Nanox Q1 Revenue Climbs 53.6% to $4.3M as RadNet Deployment Begins
NNOX•In Q1 2026 Nanox generated $4.3M revenue, up 53.6% from $2.8M in Q1 2025, led by $3.1M from teleradiology services. Non-GAAP gross loss margin improved to 4% from 15% and Nanox.ARC began commercial use at a RadNet outpatient center.
1. Q1 Financial Performance
Nanox reported $4.3 million in revenue for the quarter ended March 31, 2026, up from $2.8 million a year earlier. GAAP gross loss narrowed from 108% to 60%, while non-GAAP gross loss margin improved to 4% from 15%. Research and development expenses fell slightly to $4.8 million, and sales and marketing expenses rose to $2.2 million, driving a net loss of $14.3 million versus $13.2 million last year.
2. Commercial Deployment Progress
The company advanced execution of U.S. channel agreements and initiated system placements through its Nanox Imaging Network. A Nanox.ARC unit has been operational and integrated into routine workflow at a RadNet outpatient imaging center. Nanox also continued clinical validation efforts for its AI-enabled cardiac solution via the Cedars-Sinai collaboration.
3. Strategic Initiatives and Cost Structure
Management is prioritizing partnerships and high-visibility reference sites to accelerate market adoption. Efficiency measures have been introduced to improve the cost structure. Executives caution that commercialization pace will depend on market demand, site readiness, regulatory approvals and partner performance.
